Articles Referencing CBST
Pipeline Progress at Gilead - Analyst Blog
5/16/2013, 2:29 pm from Zacks.com in Investing, Business, Stocks
Gilead Sciences, Inc. ( GILD ) recently
presented encouraging data on its pipeline candidate idelalisib
(formerly GS-1101) from a phase II study (study 101-08: n=64). The
study is... Read >>
Cempra/Toyama Ink Deal - Analyst Blog
5/15/2013, 5:29 pm from Zacks.com in Investing, Business, Stocks
Cempra, Inc. ( CEMP ) recently
entered into an exclusive license and development agreement with a
Japanese company, Toyama Chemical Co., Ltd., a subsidiary of
FUJIFILM Holdings ( FUJIY ... Read >>
Synergy Pharma Posts Wider Loss - Analyst Blog
5/15/2013, 12:21 pm from Zacks.com in Investing, Business, Stocks
Synergy Pharmaceuticals Inc. ( SGYP ) reported a loss
of 24 cents per share in the first quarter of 2013, wider than the
year-ago loss of 13 cents and the Zacks Consensus Estimate of... Read >>
Wider-Than-Expected Loss at Athersys - Analyst Blog
5/15/2013, 10:29 am from Zacks.com in Investing, Business, Stocks
Athersys, Inc. 's ( ATHX ) first quarter
2013 adjusted net loss of 13 cents per share was wider than the
Zacks Consensus Estimate of a loss of 10 cents. Lower-than-expected
revenues were... Read >>
Celgene Attains 52-Week High - Analyst Blog
5/14/2013, 1:07 pm from Zacks.com in Investing, Business, Stocks
Shares of Celgene Corporation ( CELG ) hit a 52-week
high of $131.13 in the first half of the trading session on May 13.
This biopharmaceutical stock gained significant momentum... Read >>
NPS Pharma Incurs Narrower 1Q Loss - Analyst Blog
5/14/2013, 10:23 am from Zacks.com in Investing, Business, Stocks
NPS Pharmaceuticals, Inc. ( NPSP ) reported first
quarter 2013 net loss per share of 9 cents per share, narrower than
the Zacks Consensus Estimate of a loss of 13 cents and the... Read >>
Setback for Endo Health on Opana ER - Analyst Blog
5/13/2013, 6:05 pm from Zacks.com in Investing, Business, Stocks
Endo Health Solutions Inc. ( ENDP ) recently
suffered a setback with the US Food and Drug Administration (FDA)
turning down its request to prevent the entry of generic versions
of the... Read >>
Earnings Beat at Warner Chilcott - Analyst Blog
5/13/2013, 10:48 am from Zacks.com in Investing, Business, Earnings, Stocks
Warner Chilcott' s ( WCRX ) first quarter
2013 earnings (excluding special items) of 92 cents per share
handsomely beat the Zacks Consensus Estimate of 85 cents. Lower
selling, general... Read >>
Narrower-than-Expected Loss at MannKind - Analyst Blog
5/13/2013, 10:11 am from Zacks.com in Investing, Business, Stocks
MannKind Corporation 's ( MNKD ) loss of 15
cents per share in the first quarter of 2013 was narrower than the
Zacks Consensus Estimate of a loss of 16 cents and the year-ago
loss of 27... Read >>
Wider-than-Expected Loss at Optimer - Analyst Blog
5/10/2013, 12:23 pm from Zacks.com in Investing, Business, Stocks
Optimer Pharmaceuticals Inc. 's ( OPTR ) first quarter
2013 net loss (excluding special items) of 65 cents per share was
wider than the Zacks Consensus Estimate of a loss of 42 cents... Read >>
Good News for Cubist Pharmaceuticals - Analyst Blog
5/9/2013, 4:24 pm from Zacks.com in Investing, Business, Stocks
Cubist Pharmaceuticals, Inc. ( CBST ) recently
received encouraging news when the US Food and Drug Administration
(FDA) granted the company's antibiotic candidate
ceftolozane/tazobactam... Read >>
Earnings Beat at Endo Health, Sales Slip - Analyst Blog
5/8/2013, 6:24 pm from Zacks.com in Investing, Business, Earnings, Stocks
Endo Health Solutions' ( ENDP ) first quarter
2013 earnings (excluding special items) of $1.09 per share beat the
Zacks Consensus Estimate by a penny and increased 25% from the
year-ago... Read >>
Positive Data on Forest Combo Drug - Analyst Blog
5/7/2013, 4:23 pm from Zacks.com in Investing, Business, Stocks
Forest Laboratories, Inc. ( FRX ) and Almirall,
S.A. recently announced positive top-line data on their chronic
obstructive pulmonary disease (COPD) fixed dose combination
candidate,... Read >>
Alnylam Narrows Loss, Sales Fall - Analyst Blog
5/7/2013, 9:25 am from Zacks.com in Investing, Business, Stocks
Alnylam Pharmaceuticals Inc. 's ( ALNY ) first quarter
2013 loss of 15 cents per share was narrower than the Zacks
Consensus Estimate of a loss of 31 cents and the year-ago loss of
25... Read >>
Teva Beats on Earnings, Revenues - Analyst Blog
5/6/2013, 1:02 pm from Zacks.com in Investing, Business, Earnings, Stocks
Teva Pharmaceutical Industries ( TEVA ) reported first
quarter earnings of $1.12 per American Depositary Share (ADS), a
couple of cents above the Zacks Consensus Estimate but 23.8%... Read >>